Vnitr Lek 2010, 56(1):44-48

Clinical perspective of precancerotic states in gastroenterology and their molecular genetics

P. Mináriková1,2,*, M. Zavoral1,2
1 Interní klinika 1. lékařské fakulty UK a ÚVN Praha, přednosta prof. MUDr. Miroslav Zavoral, Ph.D.
2 Subkatedra gastroenterologie IPVZ Praha, přednosta prof. MUDr. Miroslav Zavoral, Ph.D.

Gastrointestinal tract tumours represent an important cause of death in the Czech Republic. Diagnosis of the disease at its advanced stage with progression precluding radical surgical solution is a frequent common denominator. Detection of precancerous states, including congenital genetic defects or premalignant syndromes and malignant lesions may serve as a useful tool for early detection of disease risk or disease onset. Considering the incidence of individual types of tumours, this paper focuses mainly on precancerotic states leading to malignant alterations of oesophagus, colorectum and pancreas. Apart from a concise morphological description of each premalignancy and its malignant transformation, a description of traditional molecular models of development and progression is also provided. Furthermore, we include a brief list of the most important genes contributing to the mechanism of malignant transformation in these three most important tumour diseases.

Keywords: gastrointestinal tract; tumour diseases; genetics; oesophagus; colon; rectum; pancreas; DNA; mutation

Received: September 30, 2009; Published: January 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mináriková P, Zavoral M. Clinical perspective of precancerotic states in gastroenterology and their molecular genetics. Vnitr Lek. 2010;56(1):44-48.
Download citation

References

  1. Wikipedia - the online encyclopedia, http://en.wikipedia.org/wiki/Precancerous.
  2. Epidemiologie zhoubných nádorů v České republice v roce 2007, www.svod.cz.
  3. Klein CA. Gene expression sigantures, cancer cell evolution and metastatic progression. Cell Cycle 2004; 3: 29-31. Go to original source... Go to PubMed...
  4. Toribara NW, Sleisenger MH. Screening for colorectal cancer. N Engl J Med 1995; 332: 861-867. Go to original source... Go to PubMed...
  5. Barrett N. The lower esophagus lined by columnar epithelium. Surgery 1957; 41: 881-894. Go to PubMed...
  6. Fléjou J. Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut 2005; 54 (Suppl 1): i6-i12. Go to original source... Go to PubMed...
  7. Seewald S, Ang TL, Groth S et al. Detection and endoscopic therapy of early esophageal adenocarcinoma. Curr Opin Gastroenterol 2008; 24: 521-529. Go to original source... Go to PubMed...
  8. Kaur BS, Khamnehei N, Iravani M et al. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002; 123: 60-67. Go to original source... Go to PubMed...
  9. Worthley DL, Whitehall VL, Spring KJ et al. Colorectal carcinogenesis: road maps to cancer. World J Gastroenterol 2007; 13: 3784-3791. Go to original source... Go to PubMed...
  10. Lynch HT, Lanspa S, Smyrk T et al. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I & II). Genetics, pathology, natural history, and cancer control, Part I. Cancer Genet Cytogenet 1991; 53: 143-160. Go to original source... Go to PubMed...
  11. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767. Go to original source... Go to PubMed...
  12. Capella G, Cronauer-Mitra S, Pienado MA et al. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect 1991; 93: 125-131. Go to original source... Go to PubMed...
  13. Jass JR. Colorectal cancer: a multipathway disease. Crit Rev Oncog 2006; 12: 273-287. Go to original source... Go to PubMed...
  14. Wheeler JM. Epigenetics, mismatch repair genes and colorectal cancer. Ann R Coll Surg Engl 2005; 87: 15-20. Go to original source... Go to PubMed...
  15. Watson AJ. Apoptosis and colorectal cancer. Gut 2004; 53: 1701-1709. Go to original source... Go to PubMed...
  16. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 2005; 128: 192-206. Go to original source... Go to PubMed...
  17. Tsouma A, Aggeli C, Pissimissis N et al. Circulating tumor cells in colorectal cancer: detection methods and clinical significance. Anticancer Res 2008; 28: 3945-3960.
  18. Anker P, Mulcahy H, Chen XQ et al. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999; 18: 65-73. Go to original source... Go to PubMed...
  19. Hassan MM, Bondy ML, Wolff RA et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 2007; 102: 2696-2707. Go to original source... Go to PubMed...
  20. Otsuki M, Tashiro M. Chronic pancreatitis and pancreatic cancer, lifestyle-related diseases. Intern Med 2007; 46: 109-113. Go to original source... Go to PubMed...
  21. Hruban RH, Goggins M, Parsons J et al. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6: 2969-2972.
  22. Salek C, Benesova L, Zavoral M et al. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World J Gastroenterol 2007; 13: 3714-3720. Go to original source... Go to PubMed...
  23. Salek C, Minarikova P, Benesova L et al. Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer. Anticancer Res 2009; 29: 1803-1810.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.